Mesoblast (ASX:MSB) expanded its coverage for Ryoncil to 104 million US government- and private-insured lives, according to a Thursday filing with the Australian bourse.
Ryoncil is approved by the US Food and Drug Administration for mesenchymal stromal cell therapy.
It is the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older, a separate filing showed.
Mesoblast's shares were up nearly 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。